Single Use Instrument recommendations set to stimulate reform in decontamination procedures?

Article

The recommendations for 'the use of single use instruments where possible' when performing 'high-risk' surgical procedures, has not only led to a growth in the single use market segment, but has stimulated massive reform in decontamination procedures, creating increased demand globally for reusable instruments due to new processes and longer lead times.

The recommendations for 'the use of single use instruments where possible' when performing 'high-risk' surgical procedures, has not only led to a growth in the single use market segment, but has stimulated massive reform in decontamination procedures, creating increased demand globally for reusable instruments due to new processes and longer lead times, according to ophthalmic instrument supplier John Weiss & Son, Ltd.

Although the heightened requirements for handcrafted reusable instruments remains a production priority for many manufacturers, the significant requirement for single use instruments alongside reusable products cannot be ignored.

This is evidenced by the foundation of The Eyeline Organisation, an international group of ophthalmologists whose aim is to apply cutting edge innovation to the design and quality of single use instruments. Eyeline manufactures instruments including forceps, needleholders, scissors and a variety of manipulators and probes. The ACROfine dispøz Single Use Instruments manufactured by Eyeline have recently been released by John Weiss, and are available in procedure packs for phaco, sub-tenons, oculoplastic, and intravitreal injections.

"This unique relationship will offer surgeons the single use solution they never expected," explains Michael Bench, managing director of John Weiss.

www.johnweiss.com

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.